55 Biotechnology & immunology Expanded solutions for seamless stem cell research


AMSBIO, a leading provider of innovative products and services for the life sciences community, announces the launch of its Expanded Stem Cell Synergy Solutions.


Over the last two decades AMSBIO has established itself as a leading international supplier of solutions for streamlined and efficient ES/iPS Cell Culture using feeder-free StemFit® media and iMatrix recombinant laminin extracellular matrices. Backed by knowledgeable support teams in the UK, USA, and Germany, AMSBIO has expanded its products and services across the entire stem cell workflow, from sourcing and growing to storing, differentiating, and manufacturing.


AMSBIO offers an extensive range of sources to facilitate cutting-edge stem cell research. including fresh tissues covering a wide range of donors and disease states, cell lines and a custom pluripotent stem cell (iPSC) generation service. By segmenting the stem cell workflow, AMSBIO supports researchers by simplifying the procurement process and providing valuable guidance at each stage of your stem cell research.


Discover everything you need for stem cell culture with superior expansion rates whilst maintaining genetic stability, as well as reliable solutions for long- term cryopreservation. In addition, AMSBIO offers an extensive range of leading-edge cryopreservation solutions that guarantee the integrity of your cells. For efficient stem cell differentiation toward specific cell lineages from PSCs, AMSBIO offers a specially curated differentiation product range.


To seamlessly transition your research to deployment in clinical applications, AMSBIO offer a suite of GMP-compliant manufacturing products and services trusted by a growing group of leading pharma and biotech organisations.


More information online: ilmt.co/PL/NAkz 62067pr@reply-direct.com


Cell disruption of microorganisms with mixer mills


Cell disruption is frequently the method of choice to extract cellular components from bacteria, yeast, fungi, or microalgae and is carried out either chemically or mechanically. Mechanical methods are better suited for cells with tough walls, or if the chemicals might affect the extraction and therefore need to be avoided. A common and effective method is bead beating which uses beads to shear the cells in a suspension. Bead beating can be done on a small or large scale, using different types of vials and tubes. One way is to mix the suspension with beads and use a vortex mixer. However, this procedure is slow and inconsistent, especially with a large number of samples or long disruption times. A better way is to use Retsch Mixer Mills with adapters which automate the process, making it fast, efficient and reproducible.


The MM 400 processes up to 20 samples in 1.5 or 2 ml Eppendorf tubes without cross contamination which saves time for the operator. Additionally, an adapter is available to accommodate up to eight 50 ml Falcon tubes. The optimal bead size for cell disruption varies based on the cell type; for bacteria and yeast, glass beads ranging from 0.75 to 1.5 mm are recommended, while smaller beads within the range of 0.1 to 0.5 mm are more suitable for fungi and microalgae.


For DNA or RNA extraction, smaller single-use tubes up to 2 ml are ideal, whereas larger vials like the 50 ml Falcon tubes are well-suited for processing proteins or metabolites. The optimum bead beating parameters vary according to cell type. It may take some experimenting to find the best results. Usually, 30 s (most microalgae) to 7 min (yeasts in general) of bead beating are required to fully disrupt the cells.


More information online: ilmt.co/PL/LoZA 62247pr@reply-direct.com Optimise biomanufacturing with simplifi ed cell analysis and sorting


Strain improvement and bioprocess monitoring are key factors in successful biomanufacturing processes, having significant impact on yields, operational efficiency, and overall economic viability. To master these factors, manufacturers require advanced technologies that both streamline processes and are easy to learn for inexperienced users.


The SH800 Cell Sorter from Sony Biotechnology emerges as a transformative solution, empowering users to accelerate strain improvement and simplify bioprocess monitoring. At the core of its capabilities lies the revolutionary Sorting Made Simple™ technology, positioning the system as a user-friendly gateway to the gold standards of flow cytometry and cell sorting, often considered too complex.


The SH800 system’s standout feature is its innovative microfluidic chip, a technology that ensures effortless, precise, and contamination-free sorting during strain selection and improvement. This technology not only enhances the accuracy of the process but also contributes to the overall reliability of the outcomes. The system’s advancements in high-throughput operations and consistently high-viability sorting empower users with rapid and unbiased measurements, crucial for comprehensive characterisation and stringent quality control measures.


The user-friendly design extends beyond hardware to the intuitive software of the SH800 system. Combined with advanced automation setup and calibration, the software significantly reduces the learning curve for the team. Together, these features ensure that the analysis of microbial samples becomes a seamless and efficient endeavour, promoting a smoother integration of the SH800 system into a biomanufacturing workflow.


In essence, the SH800 system transforms the landscape of strain improvement and bioprocess monitoring, making these critical factors more accessible and user-friendly for both seasoned professionals and new users alike.


More information online: ilmt.co/PL/yzpG 61903pr@reply-direct.com Biomarker discovery advances with new platform integration


Synexa Life Sciences, a global Clinical Laboratory Services provider for the biopharma industry, has announced the integration of the Olink® Target immunoassays and the Olink® Signature Q100 instrument into its extensive suite of biomarker discovery platforms.


The incorporation of Olink Signature Q100 marks a signifi cant advancement in Synexa’s commitment to delivering leading biomarker and bioanalytical solutions to its biotech and pharma clientele. The Olink Signature Q100 system facilitates the processing and analysis of Olink Target assays in disease-focused panel formats, requiring as little as 1 μL of serum, plasma, or other biological sample types. Through the profi ling of protein biomarkers, deeper insights into disease mechanisms are unveiled, aiding in the identifi cation of potential therapeutic targets and expediting the development of innovative treatments.


Justin Devine, Chief Innovation Offi cer, remarked: “By integrating the Olink platform into our service offerings, Synexa can further bolster researchers’ endeavours in translational research, patient- centric sampling, and extracellular vesicle analysis.”


Emile Lens, CEO at Synexa Life Sciences, emphasised: “The incorporation of Olink into the Synexa technology portfolio underscores our ongoing commitment to enhancing our biomarker and bioanalysis capabilities across various expertise areas, including oncology, immuno-oncology, infectious diseases, and more. The inclusion of Olink in our service portfolio enables us to address clinical research inquiries more effectively, signifi cantly broadening access to proteomics for deeper biological insights among our global clientele.”


The Olink Signature Q100 is purpose-built to meet the precise requirements of clinical laboratory services in the biotech, pharmaceutical,and contract research organisation (CRO) sectors. Offering a wide range of capabilities, including high-throughput multiplex protein biomarker measurement and data analysis, the system employs a seamless workfl ow, saving time at the lab bench. This enables researchers to process large samples and datasets effi ciently, accelerating drug discovery and enhancing personalised medicine initiatives.


More information online: ilmt.co/PL/A6B7 62343pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68